Instil Bio, Inc. Common Stock (TIL)
Instil Bio, Inc. (TIL) is a biotechnology company focused on developing personalized cell therapies for cancer treatment. The company utilizes its proprietary platform to engineer and produce tumor-infiltrating lymphocyte (TIL) therapies aimed at enhancing the immune response against solid tumors. Headquartered in the United States, Instil aims to improve outcomes for cancer patients through innovative immunotherapy solutions.
Company News
Instil Bio reported a wider loss in Q2 2025, with Non-GAAP EPS of $(2.88), missing analyst expectations. The company increased R&D spending to $6.7 million and received FDA clearance for its lead drug candidate '2510, with plans to launch a U.S. clinical trial before year-end.
Over 180 companies are developing 250+ bispecific antibodies targeting complex chronic diseases like cancer and autoimmune disorders, with innovative dual-targeting molecules offering superior therapeutic precision and efficacy.
Instil Bio (TIL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Upgrades For OPKO Health Inc (NASDAQ:OPK), Barrington Research upgraded the previous rating of Market Perform to Outperform. For the first quarter, OPKO Health had an EPS of $0.02, compared to year-ago quarter EPS of $0.08. The current stock performance of OPKO Health shows a 52-week-high of $2.85 and a 52-week-low of $1.00. Moreover, at the end ...
Hot penny stocks to watch with news this week. The post 5 Hot Penny Stocks To Watch This Week With Big News appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.